In this podcast episode, Dr. Marco Propersi delves into the CAPE COD Trial, exploring the potential impact of hydrocortisone therapy on patients with severe Community-Acquired Pneumonia admitted to the ICU. Dr. Propersi breaks down the trial's objectives, methodology, and outcomes, highlighting key findings such as the significant reduction in 28-day mortality with hydrocortisone therapy compared to placebo. He discusses the strengths and limitations of the study, emphasizing the importance of critically appraising the findings and considering factors such as patient demographics, treatment timing, and potential biases. Through detailed analysis and comparison with other studies, Dr. Propersi provides valuable insights into the implications of this research for clinical practice, suggesting that early administration of corticosteroids may offer benefits in managing severe Community-Acquired Pneumonia.